IGIV-C 10% ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
65	Primary immunodeficiency	2

65. Primary immunodeficiency

---

Clinical trials : 500 /  Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02604810 (ClinicalTrials.gov)	January 2016	6/11/2015	Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency	An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency	Primary Immunodeficiency	Biological: IGIV-C 10%;Biological: IGSC 20%	Grifols Therapeutics LLC	NULL	Completed	2 Years	75 Years	All	53	Phase 3	United States;Canada
2	NCT00220766 (ClinicalTrials.gov)	August 2002	13/9/2005	Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients	IGIV-C 10% Rapid Infusion Trial in Primary Immune Deficient Patients	Immunologic Deficiency Syndrome;Agammaglobulinemia;Severe Combined Immunodeficiency;Wiskott-Aldrich Syndrome;Common Variable Immunodeficiency	Drug: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified;Drug: Dextrose, 5% in Water	Grifols Therapeutics Inc.	NULL	Completed	18 Years	75 Years	Both	100	Phase 3	United States;Canada